26th IFPMA assembly – panel discussion I
Geneva, October 31, 2012
Panel I: “Innovation Today: Treading New Ground to Meet Global Health Needs”
Cary Adams, CEO, Union for International Cancer Control
Nigel Darby, Vice President of Biotechnologies, Chief Technology Officer GE Healthcare
David Khayat, Professor and Head of Medical Oncology, Pitié-Salpêtrière Hospital
John Lechleiter, Chairman, President, and CEO, Eli Lilly & Company
Mary Lou Valdez, Associate Commissioner for International Programs, U.S. Food and Drug Administration
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.
Learn more
Related news and resources
The development and manufacture of vaccines to protect global health (IFPMA & DCVMN)
IFPMA has partnered with DCVMN to share our industry’s expertise in vaccine development and manufacturing. This presentation illustrates the key stages and timeline to bring vaccines to the market.
Read more
IFPMA Statement at the closing of the WTO Ministerial Conference in Abu Dhabi
On 1 March, at the end of the 13th WTO Ministerial Conference, IFPMA issued a statement.
Read moreFebruary 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more